For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Attruby represents a significant change. These innovative therapies stabilize the transthyretin protein, preventing its destructive build-up and lessening the impact o